National guidelines thus do not recommend treatment with anti-H1R antagonists for the therapy of childhood AD anymore, neither systemically nor topically (AWMF S3 Leitlinie der deutschen dermatologischen Gesellschaft; [24]). The gene discussed is HRH1; the disease is Alzheimer disease.